[1] |
Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases[J]. J Allergy Clin Immunol, 2003, 112(2):252-262.
doi: 10.1067/mai.2003.1595
URL
|
[2] |
Afshar R, Medoff BD, Luster AD. Allergic asthma: a tale of many T cells[J]. Clin Exp Allergy, 2008, 38(12): 1847-1857.
doi: 10.1111/j.1365-2222.2008.03119.x
pmid: 19037961
|
[3] |
Palomares Ó, Sánchez-Ramón S, Dávila I, et al. Divergent: how IgE axis contributes to the continuum of allergic asthma and anti-IgE therapies[J]. Int J Mol Sci, 2017, 18(6): 1328.
doi: 10.3390/ijms18061328
URL
|
[4] |
Davis LA. Omalizumab: a novel therapy for allergic asthma[J]. Ann Pharmacother, 2004, 38(7-8): 1236-1242.
pmid: 15187202
|
[5] |
Okayama Y, Matsumoto H, Odajima H, et al. Roles of omalizumab in various allergic diseases[J]. Allergol Int, 2020, 69(2): 167-177.
doi: S1323-8930(20)30010-1
pmid: 32067933
|
[6] |
Pelaia C, Calabrese C, Terracciano R, et al. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness[J]. Ther Adv Respir Dis, 2018, 12: 1753466618810192.
|
[7] |
Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics[J]. Eur Respir J, 2001, 18(2):254-261.
doi: 10.1183/09031936.01.00092101
pmid: 11529281
|
[8] |
中华医学会呼吸病学分会哮喘学组. 奥马珠单抗治疗过敏性哮喘的中国专家共识(2021版)[J]. 中华结核和呼吸杂志, 2022, 45(4): 341-354.
|
[9] |
Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control[J]. J Allergy Clin Immunol, 2004, 113(1):59-65.
doi: 10.1016/j.jaci.2003.09.008
URL
|
[10] |
Bousquet J, Humbert M, Gibson PG, et al. Real-world effectiveness of omalizumab in severe allergic asthma[J]. J Allergy Clin Immunol Pract, 2021, 9(7): 2702-2714.
doi: 10.1016/j.jaip.2021.01.011
URL
|
[11] |
Yalcin AD, Uzun R. Anti-IgE significantly changes circulating interleukin-25, vitamin-D and interleukin-33 levels in patients with allergic asthma[J]. Curr Pharm Des, 2019, 25(35): 3784-3795.
doi: 10.2174/1381612825666190930095725
URL
|
[12] |
Sellitto A, De Fanis U, Balestrieri A, et al. Effects of omalizumab treatment on serum cytokine concentrations of atopic patients with chronic spontaneous urticaria[J]. Eur Ann Allergy Clin Immunol, 2017, 49(4): 171-175.
doi: 10.23822/eurannaci.1764-1489.10
pmid: 28752720
|
[13] |
Minegishi Y, Saito M. Molecular mechanisms of the immunological abnormalities in hyper-IgE syndrome[J]. Ann N Y Acad Sci, 2011, 1246: 34-40.
doi: 10.1111/nyas.2011.1246.issue-1
URL
|
[14] |
Knochelmann HM, Dwyer CJ, Bailey SR, et al. When worlds collide: Th17 and Treg cells in cancer and autoimmunity[J]. Cell Mol Immunol, 2018, 15(5): 458-469.
doi: 10.1038/s41423-018-0004-4
pmid: 29563615
|
[15] |
Boonpiyathad T, Sözener ZC, Satitsuksanoa P, et al. Immunologic mechanisms in asthma[J]. Semin Immunol, 2019, 46: 101333.
|
[16] |
Ogawa R, Suzuki Y, Kagawa S, et al. Distinct effects of endogenous interleukin-23 on eosinophilic airway inflammation in response to different antigens[J]. Allergol Int, 2015, 64 Suppl: S24-S29.
|
[17] |
Moreira AP, Cavassani KA, Ismailoglu UB, et al. The protective role of TLR6 in a mouse model of asthma is mediated by IL-23 and IL-17A[J]. J Clin Invest, 2011, 121(11): 4420-4432.
doi: 10.1172/JCI44999
pmid: 22005301
|
[18] |
Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma[J]. Am J Respir Crit Care Med, 2004, 170(6): 583-593.
doi: 10.1164/rccm.200312-1651OC
URL
|
[19] |
Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma[J]. J Allergy Clin Immunol, 2006, 117(6): 1493-1499.
doi: 10.1016/j.jaci.2006.02.028
URL
|
[20] |
Huang YC, Weng CM, Lee MJ, et al. Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy[J]. Clin Exp Allergy, 2019, 49(1): 44-53.
doi: 10.1111/cea.2019.49.issue-1
URL
|